The lack of effects of zinc and nitric oxide in initial state of pilocarpine-induced seizures.
In this study we investigated whether intracerebroventricular (i.c.v.) injection of L-NAME (a nitric oxide synthase inhibitor) or CaEDTA (an extracellular zinc chelator) or the combination of the two could affect the initial phase of pilocarpine induced (2 h) seizures. Two groups of rats were used. Animals from both groups were given with i.c.v. injections of either saline (10 microl), L-NAME (150 microg/10 microl), CaEDTA (100 mM/10 microl) or L-NAME and CaEDTA. One group received pilocarpine HCl (380 mg/kg i.p.) the other served as control. Pilocarpine HCl was injected intraperitoneally 10 min later. The behavior of the animals was observed for 2h and the intensity of their seizures was scored. The rats were then sacrificed and their brains were removed and analyzed for zinc ions by using the immersion autometallography and the TSQ fluorescence staining. All the animals which received pilocarpine HCl developed seizures. Despite treatment with L-NAME and/or CaEDTA we found that the latency and the intensity of seizures were similar in both groups investigated. The distribution of stainable zinc ions and the intensity of staining in hippocampus were not affected by pilocarpine and found unchanged after L-NAME and/or CaEDTA injections in both the control animals and the pilocarpine treated animals. The data suggest that the nitric oxide system and zinc ions do not affect pilocarpine-induced seizures in their initial state.
Noyan
Behzat
B
Department of Physiology, Medical Faculty, Uludag University, 16059 Gorukle, Bursa, Turkey. noyan@uludag.edu.tr
Jensen
Morten Skovgaard
MS
Danscher
Gorm
G
D000818:Animals; D001522:Behavior, Animal; D002614:Chelating Agents / Q000008:administration & dosage; D004195:Disease Models, Animal; D004347:Drug Interactions; D004492:Edetic Acid / Q000008:administration & dosage; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D007839:Functional Laterality / Q000187:drug effects; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007276:Injections, Intraventricular; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000008:administration & dosage; D009569:Nitric Oxide / Q000378:metabolism*; D010862:Pilocarpine; D051381:Rats; D017207:Rats, Sprague-Dawley; D012640:Seizures / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D015032:Zinc / Q000378:metabolism*
D002614:Chelating Agents; D004791:Enzyme Inhibitors; D010862:Pilocarpine; D009569:Nitric Oxide; D004492:Edetic Acid; D015032:Zinc; D019331:NG-Nitroarginine Methyl Ester